{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:00:44Z","timestamp":1793840444747,"version":"4.6.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["JP 20K16068"],"award-info":[{"award-number":["JP 20K16068"]}]},{"name":"Research Foundation for Pharmaceutical Sciences"},{"name":"Japan Council of National Hospital Pharmacy Directors"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.seizure.2020.10.017","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T03:55:02Z","timestamp":1604030102000},"page":"181-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in Japanese patients with epilepsy"],"prefix":"10.1016","volume":"83","author":[{"given":"Yoshiaki","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Shiratani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotaka","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2020.10.017_bib0005","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.10.017_bib0010","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/FTD.0000000000000274","article-title":"Perampanel serum concentrations in adults with epilepsy: effect of dose, age, sex, and concomitant anti-epileptic drugs","volume":"38","author":"Patsalos","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2020.10.017_bib0015","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/FTD.0000000000000416","article-title":"Therapeutic drug monitoring for perampanel in japanese epilepsy patients: influence of concomitant antiepileptic drugs","volume":"39","author":"Yamamoto","year":"2017","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2020.10.017_bib0020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0883073819837465","article-title":"Perampanel pharmacokinetics in children: correlation of dose with serum concentrations","volume":"34","author":"Gaudio","year":"2019","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2020.10.017_bib0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.seizure.2019.10.023","article-title":"Efficacy and serum concentrations of perampanel for treatment of drug-resistant epilepsy in children, adolescents, and young adults: comparison of patients younger and older than 12 years","volume":"73","author":"Ikemoto","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2020.10.017_bib0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.yebeh.2019.02.004","article-title":"Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy","volume":"94","author":"Ishikawa","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2020.10.017_bib0035","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1212\/WNL.0000000000001558","article-title":"Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy","volume":"84","author":"Gidal","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.seizure.2020.10.017_bib0040","first-page":"490","article-title":"Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures","volume":"54","author":"Gidal","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.10.017_bib0045","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s11064-017-2234-8","article-title":"Therapeutic drug monitoring of Lacosamide in Norway: focus on pharmacokinetic variability, efficacy and tolerability","volume":"42","author":"Svendsen","year":"2017","journal-title":"Neurochem Res"},{"key":"10.1016\/j.seizure.2020.10.017_bib0050","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.seizure.2019.02.022","article-title":"Plasma concentration and clinical effects of perampanel-The Kork experience","volume":"67","author":"Steinhoff","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2020.10.017_bib0055","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/FTD.0000000000000556","article-title":"Influence of inflammation on the pharmacokinetics of perampanel","volume":"40","author":"Yamamoto","year":"2018","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2020.10.017_bib0060","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.seizure.2020.10.017_bib0065","doi-asserted-by":"crossref","first-page":"106367","DOI":"10.1016\/j.eplepsyres.2020.106367","article-title":"Influence of stiripentol on perampanel serum levels","volume":"164","author":"Trabs","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2020.10.017_bib0070","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1111\/epi.14446","article-title":"Effect of valproic acid on perampanel pharmacokinetics in patients with epilepsy","volume":"59","author":"Contin","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.10.017_bib0075","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/epi.14596","article-title":"The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis","volume":"59","author":"Kalilani","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.10.017_bib0080","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/epi.14456","article-title":"Perampanel: Does it have broad-spectrum potential?","volume":"60","author":"Potschka","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.10.017_bib0085","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1111\/epi.14522","article-title":"Perampanel in routine clinical use in idiopathic generalized epilepsy: the 12-month GENERAL study","volume":"59","author":"Villanueva","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.10.017_bib0090","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/biom10030464","article-title":"Ionotropic glutamate receptors in epilepsy: a review focusing on AMPA and NMDA receptors","volume":"10","author":"Hanada","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.seizure.2020.10.017_bib0095","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/ane.12931","article-title":"Retrospective study of perampanel efficacy and tolerability in myoclonic seizures","volume":"138","author":"Gil-L\u00f3pez","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2020.10.017_bib0100","doi-asserted-by":"crossref","first-page":"106191","DOI":"10.1016\/j.eplepsyres.2019.106191","article-title":"An Italian multicentre study of perampanel in progressive myoclonus epilepsies","volume":"156","author":"Canafoglia","year":"2019","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2020.10.017_bib0105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/epi.14645","article-title":"A post hoc analysis of the long-term safety and efficacy of perampanel in Asian patients with epilepsy","volume":"60","author":"Inoue","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.10.017_bib0110","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.seizure.2018.09.012","article-title":"Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy","volume":"62","author":"Usui","year":"2018","journal-title":"Seizure"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120303356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120303356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:57:20Z","timestamp":1761011840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131120303356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":22,"alternative-id":["S1059131120303356"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2020.10.017","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in Japanese patients with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2020.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}